Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing This new financing will support broad late-stage clinical development program for visugromab, CatalYm's lead product candidate in cancer immunotherapy.After a first investment as co-lead investor in CatalYm's €50 million series C financing (November 2022), Jeito's new participation in this oversubscribed round, alongside new international biopharma investors, confirms CatalYm's strong progress and pot ...